WCLC2020 Abstract
其实本来想，去年正好在亚洲，路费便宜也不需要倒时差去长长见识，还想去再品尝下面包冰激凌，然后就被腐朽的资本主义抗疫神操作弄得没有然后了。。。。
18号Leclaza(Lazertinib)被南韩MFDS批准治疗EGFR T790M+ NSCLC，也比较应景
不管怎么样，祝这对组合三期可以有一个优效结果吧
主要更新OA - Oral Session、MA - Mini Oral Session和FP - Featured Posters部分，而P - Posters因为太多，这次先不管了
FP03 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
FP03.03 - Clinical Activity of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer
FP13 - Immunotherapy (Phase II/III Trials)
这部分主要是大临床随访更新
FP13.01 - 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC
对比下
FP13.02 - Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
FP13.03 - IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC
FP13.04 - KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
FP14 - Targeted Therapy - Clinically Focused
FP14.02 - A Phase II Study of Osimertinib versus Combination of Osimertinib and Chemotherapy for EGFR and T790M-Mutation Positive NSCLC
三代TKI加上化疗后并没有卵用
FP14.03 - Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
Osi+Savo治疗EGFRm且cMET扩增/过表达的NSCLC：
由于患者接受过≥1L的EGFR TKI，所以其中no prior 3G TKI且T790M neg的部分才真正体现出联合的协同，相比之前23人的结果，这次Cohort B部分和Cohort D的缓解率都没有下降，另外先前3G TKI经治患者的缓解率33%，所以这些患者但如果只用Savo会是怎样的结果
no prior 3G TKI且T790M+患者的ORR 67%，这个和AURA3中Osi单药的接近，这时候虽然患者也是cMET+，但是似乎看不到Savo的影响
所以Savo单药到底是什么样
FP14.06 - Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study
算是一个1/2L pooled analysis
FP14.07 - Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
FP14.08 - Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
这也没什么好说的，鬼知道多少比例用过avastin
FP14.09 - Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
FP14.10 - Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC
FP14.11 - Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study
FP14.15 - Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies.
FP14.17 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy
OA02 - Updates in Locally Advanced NSCLC
OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799
KN799和PACIFIC有所不同，前者是联合cCRT，后者是cCRT后未进展患者中的维持，所以这里比较也没有太大意义
一项2期研究，cohort A不区分组织分型，B则只入非鳞，所以化疗方案有所差别，两组ORR 在70%上下，1年PFS在66%上下，1年OS 分别81.2%和88.0%
另外PD-L1≥1%的ORR 比PD-L1＜1%的略高，但也差距不大，另外ORR在不同组织学分型间无差异
OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC
OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
患者接受了4/6/8mpk三个剂量水平 DS-1062的治疗，分别81%和95%接受过ICI和化疗，可评估疗效人群的ORR 26.4%(1 CR+32 PR，19例确认，4例待确认)
29例确认患者的患者＞80%患者缓解6个月以上，三个剂量组的DCR分别79%、75%和79%
安全性方面，12例（9%）患者报道ILD，主要是在6mpk和8mpk组，分别1例（4%，Gr2）和11例（14%，7例Gr2.4例Gr3-5）；11%因为TEAE终止治疗
其实看DS8201上市后的数据，ILD基本可控
OA03.04 - Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
靶向HER3单药意思也不大了？！
OA04 - New Data from Rare EGFR Alterations
首先是EGFRex20ins NSCLC，武田君家TAK-788 vs 光头强的 JNJ-372，其实疗效是不相上下的，可能因为后者是研究者评估的缘故，数字上好看一些，但是安全性数字的确是后者更好一些，不管是≥Gr3的TRAE还是因为AE终止治疗的比例，也是小分子设计上的无奈
OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
OA04.04 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches
P77.01 - Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC
雪中送炭不指望了，安全性好，往1L看看能不能锦上添花？
P77.02 - Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
这个之前腹黑过了，可能和Pembro联用会更好一些
P77.03 - A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
P78.01 - Nivolumab in Second Line Non-Small Cell Lung Cancer – Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057